DBV Technologies (DBVT) Restructuring Costs (2020 - 2021)
DBV Technologies (DBVT) posted quarterly Restructuring Costs of -$920000.0 for Q4 2021, down 136.09% year-on-year from $2.5 million in Q4 2020, and down 136.09% on a QoQ basis from $2.5 million in Q4 2020.
DBV Technologies (DBVT) Restructuring Costs (2020 - 2021) Analysis & Trends
DBV Technologies (DBVT) has reported Restructuring Costs for 2 consecutive years, with -$920000.0 the latest figure, recorded in Q4 2021.
- Quarterly Restructuring Costs fell 136.09% year-over-year to -$920000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.6 million (changed N/A YoY) and the FY2021 annual result came in at -$920000.0, down 103.91% from the prior year.
- Restructuring Costs slipped to -$920000.0 in Q4 2021 per DBVT's latest filing, from $2.5 million in the prior quarter.
- Over the last five years, Restructuring Costs for DBVT reached as high as $21.3 million in Q2 2020 and fell as low as -$920000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -920,000.00 |
| Dec 31, 2020 | 2.55 Mn |
| Sep 30, 2020 | -286,000.00 |
| Jun 30, 2020 | 21.29 Mn |